Christopher J Butler

US Patent:

20170210463, Jul 27, 2017

Filed:

Sep 30, 2015

Appl. No.:

15/501100

Inventors:

- Stratford CT, US
Michael J. Kostoss - North Branford CT, US
Eric Lucien Nussenblatt - Stamford CT, US
Justin Thomas - New Haven CT, US
Christopher Paul Butler - Frisco TX, US
Brandon Michael Cerge - West Palm Beach FL, US

International Classification:

B64C 27/00
B64C 27/82
B64C 27/10

Abstract:

An aircraft is provided including an airframe, an extending tail, and a counter rotating, coaxial main rotor assembly including an upper rotor assembly with an upper blade and a lower rotor assembly with a lower blade. A first antenna in one of upper blade and the lower blade, and a second antenna in the other of the upper blade and the lower blade. An oscillator to apply an excitation signal to the first antenna. A blade proximity monitor to monitor a magnitude of the excitation signal and an output signal from the second antenna to determine a distance between the upper blade and the lower blade.

US Patent:

20160002264, Jan 7, 2016

Filed:

Dec 4, 2013

Appl. No.:

14/653549

Inventors:

- New York NY, US
Brian Thomas O'Neill - Haddam CT, US
Christopher Ryan Butler - Canton MA, US
Erik Alphie LaChapelle - Johnston RI, US

Assignee:

PFIZER INC. - New York NY

International Classification:

C07D 513/04

Abstract:

The present invention provides compounds of formula I,wherein the variables R, R, Rand b are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20150376207, Dec 31, 2015

Filed:

Feb 2, 2014

Appl. No.:

14/767414

Inventors:

- New York NY, US
Brian Thomas O'Neill - Haddam CT, US
Christopher Ryan Butler - Canton MA, US
Elizabeth Mary Beck - Edinburgh, GB

Assignee:

PFIZER INC. - New York NY

International Classification:

C07D 513/04

Abstract:

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I,and the variables Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.